Symptom Severity and Glucocorticoid Dosing in Patients With Polymyalgia Rheumatica and Obesity

Area of Science:

• Rheumatology
• Clinical Medicine
• Inflammatory Disorders

Background:

• Polymyalgia rheumatica (PMR) is a common inflammatory condition in the elderly, causing pain and stiffness.
• Obesity's impact on rheumatic disease activity is established, but its specific role in PMR is not fully understood.

Purpose of the Study:

• To investigate the association between high body mass index (BMI) and the severity and treatment outcomes of polymyalgia rheumatica.
• To determine if obesity influences symptom perception or disease activity in PMR patients.

Main Methods:

• A post hoc analysis of 83 recent-onset PMR patients over 6 months.
• Data collected included clinical examinations, laboratory tests, girdle ultrasound, mHAQ, SF-36, VAS scores, and prednisone dosage.
• Patients were stratified based on BMI to compare outcomes.

Main Results:

• Obese PMR patients reported significantly higher shoulder pain, global pain, fatigue, and lower quality of life scores at baseline.
• Despite similar initial prednisone doses, obese patients required higher mean daily doses at 6 months and were more likely to exceed standard protocols.
• Clinical, laboratory, and ultrasound findings were comparable between obese and non-obese groups, suggesting subjective pain differences.

Conclusions:

• Obesity significantly impacts symptom severity and prednisone requirements in polymyalgia rheumatica.
• The findings suggest that altered pain perception, rather than increased inflammation, may explain the differences observed in obese PMR patients.
• Healthcare providers should consider patient BMI when assessing PMR symptoms and determining appropriate prednisone treatment strategies.